Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 USD | -1.75% | -11.76% | -24.87% |
Financials (USD)
Sales 2024 * | 397M | Sales 2025 * | 486M | Capitalization | 944M |
---|---|---|---|---|---|
Net income 2024 * | -126M | Net income 2025 * | -63M | EV / Sales 2024 * | 2.97 x |
Net Debt 2024 * | 234M | Net Debt 2025 * | 259M | EV / Sales 2025 * | 2.47 x |
P/E ratio 2024 * |
-7.38
x | P/E ratio 2025 * |
-13.7
x | Employees | 536 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
Latest transcript on BioCryst Pharmaceuticals, Inc.
1 day | -1.75% | ||
1 week | -11.76% | ||
Current month | -11.42% | ||
1 month | -11.24% | ||
3 months | -21.88% | ||
6 months | -23.21% | ||
Current year | -24.87% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Michael Jones
DFI | Director of Finance/CFO | 54 | 10-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 0 M€ | 0.00% | - | |
0.20% | 0 M€ | 0.00% | - | |
0.18% | 1,026 M€ | +6.11% | - | |
0.13% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 4.5 | -1.75% | 2,956,572 |
24-04-17 | 4.58 | -0.65% | 4,055,194 |
24-04-16 | 4.61 | -1.28% | 1,979,399 |
24-04-15 | 4.67 | -2.10% | 2,496,660 |
24-04-12 | 4.77 | -6.47% | 4,525,575 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.87% | 944M | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- BCRX Stock